Quest Diagnostics Incorporated $DGX Shares Acquired by Versor Investments LP

Versor Investments LP increased its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 198.7% in the third quarter, Holdings Channel reports. The firm owned 6,386 shares of the medical research company’s stock after buying an additional 4,248 shares during the period. Versor Investments LP’s holdings in Quest Diagnostics were worth $1,217,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Lebenthal Global Advisors LLC grew its holdings in Quest Diagnostics by 117.5% during the 3rd quarter. Lebenthal Global Advisors LLC now owns 5,034 shares of the medical research company’s stock worth $959,000 after acquiring an additional 2,720 shares in the last quarter. Rakuten Investment Management Inc. purchased a new stake in shares of Quest Diagnostics during the 3rd quarter worth $4,713,000. Pacer Advisors Inc. grew its stake in shares of Quest Diagnostics by 2,531.6% during the third quarter. Pacer Advisors Inc. now owns 450,898 shares of the medical research company’s stock worth $85,932,000 after purchasing an additional 433,764 shares in the last quarter. TKG Advisors LLC increased its holdings in Quest Diagnostics by 125.1% in the third quarter. TKG Advisors LLC now owns 14,596 shares of the medical research company’s stock valued at $2,782,000 after buying an additional 8,112 shares during the last quarter. Finally, Ethic Inc. raised its stake in Quest Diagnostics by 144.2% in the third quarter. Ethic Inc. now owns 14,424 shares of the medical research company’s stock valued at $2,749,000 after buying an additional 8,518 shares in the last quarter. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO J. E. Davis sold 55,093 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $192.22, for a total value of $10,589,976.46. Following the sale, the chief executive officer directly owned 120,480 shares in the company, valued at $23,158,665.60. This represents a 31.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mark E. Delaney sold 7,946 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $187.35, for a total transaction of $1,488,683.10. Following the completion of the transaction, the senior vice president directly owned 7,530 shares of the company’s stock, valued at $1,410,745.50. The trade was a 51.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 64,289 shares of company stock worth $12,318,360 in the last ninety days. Insiders own 8.16% of the company’s stock.

Quest Diagnostics Trading Up 0.3%

Shares of DGX stock opened at $191.30 on Tuesday. The stock has a market cap of $21.28 billion, a P/E ratio of 22.45, a P/E/G ratio of 2.41 and a beta of 0.66. Quest Diagnostics Incorporated has a fifty-two week low of $157.20 and a fifty-two week high of $197.55. The business has a fifty day simple moving average of $181.33 and a 200-day simple moving average of $181.51. The company has a quick ratio of 1.04, a current ratio of 1.13 and a debt-to-equity ratio of 0.71.

Analysts Set New Price Targets

DGX has been the topic of a number of recent analyst reports. Mizuho increased their price objective on Quest Diagnostics from $190.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, October 17th. Barclays raised Quest Diagnostics from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research report on Friday, January 30th. Jefferies Financial Group increased their price objective on Quest Diagnostics from $200.00 to $215.00 and gave the stock a “buy” rating in a research report on Tuesday, October 21st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Quest Diagnostics in a report on Monday, December 29th. Finally, Leerink Partners upped their price objective on Quest Diagnostics from $203.00 to $210.00 and gave the stock an “outperform” rating in a report on Tuesday, October 21st. Eight research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $198.50.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.